^
    Back
    Association details:
    Biomarker:MYC amplification
    Cancer:Acute Myelogenous Leukemia
    Drug:Venclexta (venetoclax) (Bcl2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Rinsho Ketsueki
    Title:

    Prompt cytogenetic response by venetoclax plus azacitidine regimen in a patient with AML harboring double-minute chromosomes with MYC gene amplification

    Published date:
    08/07/2023
    Excerpt:
    Finally, she was diagnosed with AML with dmin via MYC amplification and was administered with venetoclax plus azacitidine chemotherapy...Venetoclax plus azacitidine could be an effective regimen for the poor prognosis of AML with dmin through MYC amplification.
    Secondary therapy:
    azacitidine
    DOI:
    10.11406/rinketsu.64.626